REHOVOT, Israel - U.S. health officials estimate that more Americans will die during this decade of hepatitis C (HCV) infection than AIDS.
Officials at XTL Biopharmaceuticals Ltd. are trying to make a difference in these statistics. After successfully passing Phase IA clinical trails earlier this year with their drug XTL-002, researchers have announced the commencement of a Phase IB clinic study. The drug is a fully human, high-affinity monoclonal antibody that has reduced the viral levels of HCV virus.
The World Health Organization (WHO) estimates some 170 million people worldwide suffer from chronic HCV. There are 4 million carriers of the virus in the United States alone.
CDC Strategies Preventing Hospital-Onset C difficile Effectiveness Inconclusive in Testing
April 15th 2024Hospitals using CDC prevention strategies had different incidences of hospital-associated Clostridioides difficile infection compared to those that didn't, but the reasons are not necessarily the strategies themselves.
Unlocking the Power of AI in Hospital Infection Prevention: A Sustainable Approach to HAIs
April 11th 2024Read on about how, as hospitals grapple with the costly burden of healthcare-associated infections (HAIs), artificial intelligence (AI) emerges as a game-changer in revolutionizing infection prevention strategies.
Deeds to Reality: A Journey of Immigration and Obstacles With Carole W. Kamangu, MPH, RN, CIC
April 9th 2024Carole W. Kamangu, MPH, RN, CIC, shares her inspiring journey from the Democratic Republic of Congo to health care leadership in the US today. (This is the French translation of the interview with Carole W. Kamangu.)